A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: A California Cancer Consortium Study

Mark H. Kirschbaum, Kenneth A. Foon, Paul Frankel, Christopher Ruel, Bernadette Pulone, Joseph Tuscano, Edward M. Newman

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

We performed a phase II study of belinostat in patients with acute myeloid leukemia (AML). In this open label phase II study (NCT00357032), patients with relapsed/refractory AML, or newly diagnosed patients with AML over the age of 60, were eligible. Belinostat was administered intravenously (IV) at a dose of 1000 mg/m2 daily on days 15 of a 21-day cycle until progression or unacceptable toxicity. The primary endpoint was complete response (CR) rate, with secondary endpoints of overall response rate (CR partial response [PR]), time to treatment failure (TTF), overall survival and safety. Twelve eligible patients with AML were enrolled, of whom six had received at least one prior line of therapy. No CR or PR was seen. Four patients had stable disease for at least five cycles. Grade 3 non-hematological toxicities occurred in four patients. Belinostat as monotherapy has minimal single-agent effect in AML on this dosing schedule.

Original languageEnglish (US)
Pages (from-to)2301-2304
Number of pages4
JournalLeukemia and Lymphoma
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2014

Keywords

  • Histone deacetylase inhibitor
  • Leukemia
  • Phase II

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: A California Cancer Consortium Study'. Together they form a unique fingerprint.

Cite this